Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 13/20 | 1.00 |
| ▸ | RAB9A | P51151 | 13/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 7/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10347638 | 0.98 | NPC1 (0.96) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| Hydrochloric Acid SCHEMBL4255724 | 0.98 | NPC1 (0.96) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| Trifluoroacetic Acid SCHEMBL5025946 | 0.91 | NPC1 (0.82) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL30917341 | 0.85 | NPC1 (0.74) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL261022 | 0.85 | NPC1 (0.74) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL3930292 | 0.84 | NPC1 (0.72) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL27609695 | 0.84 | NPC1 (0.72) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL1819290 | 0.84 | NPC1 (0.72) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL27609657 | 0.84 | NPC1 (0.72) | NPC1RAB9AKDM4ETDP1HKDC1 | |
| SCHEMBL162869 | 0.84 | NPC1 (0.72) | NPC1RAB9AKDM4ETDP1HKDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 841 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121370882-B | Pharmaceutical composition of avibactam sodium and preparation method thereof | 哈药集团技术中心 | 2026-05-12 | — | — | CN | claimed |
| CN-119330908-A | Synthesis and application of difunctional fluorescent probe for simultaneously distinguishing and detecting superoxide anions and viscosity | 湖南工业大学 | 2025-01-21 | — | — | CN | claimed |
| CN-119330959-A | Synthesis and application of difunctional fluorescent probe for simultaneously distinguishing and detecting superoxide anions and hydrogen sulfide | 湖南工业大学 | 2025-01-21 | — | — | CN | claimed |
| CN-117586477-A | Modified epoxy resin, preparation method and application thereof, and modified aqueous epoxy emulsion | 江苏富琪森新材料有限公司 | 2024-02-23 | — | — | CN | claimed |
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | claimed |
| CN-112105604-B | Novel compounds exhibiting intestinal peptidase inhibitory activity | 株式会社LG化学 | 2024-01-09 | — | — | CN | claimed |
| CN-117050300-A | Polylysine-based polymer adjuvant material, and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2023-11-14 | — | — | CN | claimed |
| EP-3778577-B1 | NOVEL COMPOUND EXHIBITING ENTEROPEPTIDASE INHIBITORY ACTIVITY | LG CHEMICAL LTD (KR) | 2023-08-30 | — | — | EP | claimed |
| CN-111511731-B | Olefin compounds as modulators of the farnesol X receptor | 百时美施贵宝公司 | 2023-05-23 | — | — | CN | claimed |
| CN-111278817-B | Polycyclic compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-05-16 | — | — | CN | claimed |
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | claimed |
| US-7078565-B2 | Benzamide derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM PLC (GB) | 2006-07-18 | — | — | US | claimed |
| EP-1440052-B1 | BENZAMIDE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2005-12-14 | — | — | EP | claimed |
| EP-1333824-B1 | TREATMENT OF SEXUAL DYSFUNCTION WITH BOMBESIN RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-09-07 | — | — | EP | claimed |
| CN-1518445-A | Treatment of sexual dysfunction | 沃纳-兰伯特公司 | 2004-08-04 | — | — | CN | claimed |
| US-20040116440-A1 | Bombesin receptor antagonists | WARNER-LAMBERT COMPANY LLC | 2004-06-17 | — | — | US | claimed |
| US-20040087561-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY LLC | 2004-05-06 | — | — | US | claimed |
| EP-1334100-A1 | BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-13 | — | — | EP | claimed |
| US-20020169101-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY | 2002-11-14 | — | — | US | claimed |
| WO-2002040469-A1 | BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087561-A1 | Treatment of sexual dysfunction | BRS3, MME, ECE1 | NPC1 2600/4885RAB9A 1920/4885KDM4E 3348/4885 |
| US-20020169101-A1 | Treatment of sexual dysfunction | BRS3, MME, ECE1 | NPC1 2600/4885RAB9A 1920/4885KDM4E 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.